SCHEMBL6035558

SCHEMBL6035558

Cc1nccc(C(=O)OCc2ccccc2)c1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
TSHR P16473 3/20 0.53
RAB9A P51151 2/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
ALDH1A1 P00352 3/20 0.51
TDP1 Q9NUW8 4/20 0.50
EGLN1 Q9GZT9 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 3/20 0.47
PRMT5 O14744 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
MEN1 O00255 1/20 0.46
HSP90AA1 P07900 1/20 0.46
LMNA P02545 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16789584 0.82 ALDH1A1 (0.64) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL31354660 0.82 ALDH1A1 (0.64) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL6266108 0.81 POLB (0.69) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL15716659 0.81 ALDH1A1 (0.67) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL31354683 0.78 ALDH1A1 (0.68) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL19329397 0.77 POLB (0.64) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL25541337 0.77 RAB9A (0.50) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL20201216 0.77 ALDH1A1 (0.54) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL8980648 0.77 ALDH1A1 (0.58) POLBL3MBTL1TSHRRAB9ACASP3
SCHEMBL25373071 0.77 L3MBTL1 (0.47) POLBL3MBTL1TSHRRAB9ACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 POLB 4532/4885L3MBTL1 1040/4885TSHR 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.